ZENLISTIQ

Serial Number 85864152
601

Registration Progress

Application Filed
Mar 1, 2013
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

ZENLISTIQ

Basic Information

Serial Number
85864152
Filing Date
March 1, 2013
Abandonment Date
September 24, 2013
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
601
Status Date
Sep 25, 2013
Classes
005

Rights Holder

Eli Lilly and Company

03
Address
Lilly Corporate Center
Indianapolis, IN 46285

Ownership History

Eli Lilly and Company

Original Applicant
03
Indianapolis, IN

Legal Representation

Attorney
Robert E. Lee, Jr.

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

9 events
Date Code Type Description Documents
Sep 25, 2013 ABN1 O ABANDONMENT - EXPRESS MAILED Loading...
Sep 25, 2013 MAB1 O ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT Loading...
Sep 24, 2013 EXAR I TEAS EXPRESS ABANDONMENT RECEIVED Loading...
Jun 13, 2013 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 13, 2013 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 13, 2013 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 13, 2013 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 7, 2013 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 5, 2013 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005